Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

被引：1128

作者：

Watson, Philip A. ^{[1
]}

Arora, Vivek K. ^{[2
]}

Sawyers, Charles L. ^{[1
,3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA

[2] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO 63130 USA

[3] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA

来源：

NATURE REVIEWS CANCER | 2015年 / 15卷 / 12期

基金：

美国国家卫生研究院;

关键词：

SMALL-CELL CARCINOMA; BRCA MUTATION CARRIERS; ABIRATERONE ACETATE; SPLICE VARIANTS; POLY(ADP-RIBOSE) POLYMERASE; PROGESTERONE-RECEPTOR; WITHDRAWAL SYNDROME; ANTITUMOR-ACTIVITY; MOLECULAR CHARACTERIZATION; SELECTIVE-INHIBITION;

D O I：

10.1038/nrc4016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR) signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to the development of novel agents targeting the AR pathway that are now in widespread clinical use. These drugs prolong the survival of patients with late-stage prostate cancer but are not curative. In this Review, we highlight emerging mechanisms of acquired resistance to these contemporary therapies, which fall into the three broad categories of restored AR signalling, AR bypass signalling and complete AR independence. This diverse range of resistance mechanisms presents new challenges for long-term disease control, which may be addressable through early use of combination therapies guided by recent insights from genomic landscape studies of CRPC.

引用

页码：701 / 711

页数：11

共 148 条

[11] Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer [J].

Barbieri, Christopher E. ;

Baca, Sylvan C. ;

Lawrence, Michael S. ;

Demichelis, Francesca ;

Blattner, Mirjam ;

Theurillat, Jean-Philippe ;

White, Thomas A. ;

Stojanov, Petar ;

Van Allen, Eliezer ;

Stransky, Nicolas ;

Nickerson, Elizabeth ;

Chae, Sung-Suk ;

Boysen, Gunther ;

Auclair, Daniel ;

Onofrio, Robert C. ;

Park, Kyung ;

Kitabayashi, Naoki ;

MacDonald, Theresa Y. ;

Sheikh, Karen ;

Vuong, Terry ;

Guiducci, Candace ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Carter, Scott L. ;

Saksena, Gordon ;

Voet, Douglas ;

Hussain, Wasay M. ;

Ramos, Alex H. ;

Winckler, Wendy ;

Redman, Michelle C. ;

Ardlie, Kristin ;

Tewari, Ashutosh K. ;

Mosquera, Juan Miguel ;

Rupp, Niels ;

Wild, Peter J. ;

Moch, Holger ;

Morrissey, Colm ;

Nelson, Peter S. ;

Kantoff, Philip W. ;

Gabriel, Stacey B. ;

Golub, Todd R. ;

Meyerson, Matthew ;

Lander, Eric S. ;

Getz, Gad ;

Rubin, Mark A. ;

Garraway, Levi A. .

NATURE GENETICS, 2012, 44 (06) :685-U107

[12]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[13] Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity [J].

Beltran, Himisha ;

Yelensky, Roman ;

Frampton, Garrett M. ;

Park, Kyung ;

Downing, Sean R. ;

MacDonald, Theresa Y. ;

Jarosz, Mirna ;

Lipson, Doron ;

Tagawa, Scott T. ;

Nanus, David M. ;

Stephens, Philip J. ;

Mosquera, Juan Miguel ;

Cronin, Maureen T. ;

Rubin, Mark A. .

EUROPEAN UROLOGY, 2013, 63 (05) :920-926

[14] Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets [J].

Beltran, Himisha ;

Rickman, David S. ;

Park, Kyung ;

Chae, Sung Suk ;

Sboner, Andrea ;

MacDonald, Theresa Y. ;

Wang, Yuwei ;

Sheikh, Karen L. ;

Terry, Stephane ;

Tagawa, Scott T. ;

Dhir, Rajiv ;

Nelson, Joel B. ;

de la Taille, Alexandre ;

Allory, Yves ;

Gerstein, Mark B. ;

Perner, Sven ;

Pienta, Kenneth J. ;

Chinnaiyan, Arul M. ;

Wang, Yuzhuo ;

Collins, Colin C. ;

Gleave, Martin E. ;

Demichelis, Francesca ;

Nanus, David M. ;

Rubin, Mark A. .

CANCER DISCOVERY, 2011, 1 (06) :487-495

[15] Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone [J].

Bianchini, D. ;

Lorente, D. ;

Rodriguez-Vida, A. ;

Omlin, A. ;

Pezaro, C. ;

Ferraldeschi, R. ;

Zivi, A. ;

Attard, G. ;

Chowdhury, S. ;

de Bono, J. S. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) :78-84

[16] Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer [J].

Bitting, Rhonda L. ;

Armstrong, Andrew J. .

[17] Progesterone receptor expression in human prostate cancer: Correlation with tumor progression [J].

Bonkhoff, H ;

Fixemer, T ;

Hunsicker, I ;

Remberger, K .

PROSTATE, 2001, 48 (04) :285-291

[18]

Bramson HN, 1997, J PHARMACOL EXP THER, V282, P1496

[19] Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis [J].

Brasso, Klaus ;

Thomsen, Frederik B. ;

Schrader, Andres J. ;

Schmid, Sebastian C. ;

Lorente, David ;

Retz, Margitta ;

Merseburger, Axel S. ;

von Klot, Christoph A. ;

Boegemann, Martin ;

de Bono, Johann .

EUROPEAN UROLOGY, 2015, 68 (02) :317-324

[20] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

← 1 2 3 4 5 6 7 8 9 10 →